Organization

We are a skilled team of pharma and R&D professionals with extensive big pharma and biotech experience in drug discovery and development for several products now launched on the global market.

Management

Prof. Owe Orwar

Chief Executive Officer (CEO), founder and board member

Prof. Orwar has over 20 years of experience in the pharma and biotech industry, spanning across discovery and early research phases to preclinical and clinical development. He has previously held executive positions such as Global VP for R&D at Sanofi and member of their Global Steering Committee, and was President for R&D at Piramal Healthcare as well as professor at the department of physical chemistry at Chalmers University of Technology in Gothenburg, Sweden. With a Ph.D. in Chemistry from University of Gothenburg, post-doctoral studies at Stanford University, U.S., he has been awarded numerous times for his research accomplishments.

Dr. Carolina Trkulja

Chief Scientific Officer (CSO), founder and board member

Dr. Trkulja received a Ph.D. in biochemistry from Chalmers University of Technology in Gothenburg, Sweden. In her role, she is responsible for proteomics and pharmacology combined with her solid experience in research and development of antibodies. She has published her research in several top-tier scientific journals.

Göran Gannedahl, M.D., Ph.D.

Chief Medical Officer (CMO)

Dr. Gannedahl has a long experience from the medical and pharmaceutical industry within the functions medical affairs, clinical research and business development. Combined with his expertise in oncology, translational medicine as well as the U.S. Food and Drug Administration and the needed requirements of drug development such as Good Laboratory Practice (GLP) certification, gives him an edge in the field. He is a medical doctor from Karolinska Institute, has a Ph.D. in Medicine from Uppsala University and has held positions as Global Head of Science Operations at Novartis, VP of R&D in Medical Affairs at Pronova Biopharma, and Executive Global Medical Affairs Leader at AstraZeneca.

Lotta Ostler, Lawyer

Chief Operating Officer & Legal

Ostler holds a Master of Laws, tax and company law, from the University of Gothenburg. She has several years of experience from working with business law in start-ups and at the Swedish chamber of commerce. Ostler is a founder of several tech companies and an active investor. She also has experience as a board member, business coach and CEO.

Scientific Advisory Board

Dr. Kjell Andersson Med. Chemistry

Member of the Scientific Advisory Board

Dr. Andersson has a background in medicinal chemistry, synthetic organic chemistry, drug discovery and drug development and is particularly knowledgeable in cardiovascular-gastrointestinal diseases and central nervous system (CNS). He is currently a chemistry consultant and founder of KemiKAN. Prior to this, he has held various executive positions within drug discovery such as acting Head of Medicinal Chemistry at AstraZeneca Mölndal but is also the inventor of the drugs Tesaglitazar (GALIDA) and Clevidipine (CLEVIPREX). Dr. Andersson holds a Ph.D. in Physical Organic Chemistry from the University of Gothenburg, Sweden.

Prof. Elias Arnér, M.D. Ph.D.

Member of the Scientific Advisory Board

Prof. Arnér is a professor in biochemistry, focusing on redox biology and cancer research at the Department of medical biochemistry and biophysics (MBB), Karolinska Institute in Stockholm, Sweden. In addition to being considered a world authority of redox enzymology Prof. Arnér is also highly involved in education. He received his Ph.D. in medicine and medical degree from the Karolinska Institute, and a post-doctoral degree from Ludwig Maximilian University of München, Germany. He has also been an invited lecturer and chair in several conferences, and serves as an editorial board member of prominent journals such as JBC and BBA.

Prof. Rolf Karlsten, M.D.

Member of the Scientific Advisory Board

Prof. Karlsten is currently the Head of the Multidisciplinary Pain Centre and Rehabilitation Medicine at Uppsala University Hospital, Sweden. He has a broad experience in pain research and management, medical in-licensing, R&D and projects in clinical development. Previously, he has held positions such as Medical Science Director at AstraZeneca, Senior Consultant at Uppsala University Hospital, and has worked with KOL networks in Europe, the U.S. and Japan. His background of studies includes M.D. and a Ph.D. in Medical Science from Uppsala University, Sweden, and a diploma in Pharmaceutical Medicine from the Karolinska Institute in Stockholm, Sweden.

Alan Hatfield, M.D.

Member of the Scientific Advisory Board

Hatfield is currently serving as a Contractor for the Global Medicines Development at AstraZeneca in Washington DC., U.S. He has a background in clinical oncology, clinical studies and management in drug developing companies, and long experience in leading positions, such as President Clinical R&D of Piramal Enterprises Ltd., Head of Global Clinical Program for Gleevec at Novartis and Medical Director of Enzastaurin at Eli Lilly. He received his medical degree at The Ohio State University College of Medicine, followed by residency at Duke University and activities at the National Cancer Institute, U.S. National Institute of Health.

Board of Directors

Hans-Peter Ostler

Chairman

Hans-Peter Ostler is Head of Foundation Services, Regional Head Private Banking and Asset Management at Danske Bank. He is also an active investor and has an in-depth and broad background in economics and financials. Ostler is an experienced board member in Swedish biotech companies and has held high profile positions within the bank and investment sector at Ancoria Insurance Public Lt., Ålandsbanken, UBS Wealth Management and Swedbank.

Prof. Owe Orwar

Chief Executive Officer (CEO), founder and board member

Prof. Orwar has over 20 years of experience in the pharma and biotech industry, spanning across discovery and early research phases to preclinical and clinical development. He has previously held executive positions such as Global VP for R&D at Sanofi and member of their Global Steering Committee, and was President for R&D at Piramal Healthcare as well as professor at the department of physical chemistry at Chalmers University of Technology in Gothenburg, Sweden. With a Ph.D. in Chemistry from University of Gothenburg, post-doctoral studies at Stanford University, U.S., he has been awarded numerous times for his research accomplishments.

Dr. Carolina Trkulja

Chief Scientific Officer (CSO), founder and board member

Dr. Trkulja received a Ph.D. in biochemistry from Chalmers University of Technology in Gothenburg, Sweden. In her role, she is responsible for proteomics and pharmacology combined with her solid experience in research and development of antibodies. She has published her research in several top-tier scientific journals.

Dr. Claes Post

Board member

Dr.Post, M Pharm, Pharm Dr and professor of neuropharmacology, has more than 30 years of experience from senior executives in pharmaceutical- and biotech companies, including experience from drug discovery and development of pharmaceuticals, regulatory issues and marketing. Claes has previously worked as Senior Vice President (R&D) at Astra Pain Control AB (Södertälje), Vice President at Astra Draco AB (Lund), Senior Vice President at Pharmacia and Pharmacia&Upjohn (Milan, Italy and Stockholm). He has had senior positions in the technology transfer offices at Karolinska Institute and Linköping university. Claes was Partner at Danske Life Science, Venture Partner at Nordic Biotech (Copenhagen) and Investment Manager at Almi Invest AB. Currently Claes is Member of four Swedish Life Science start-up companies.

Lars Molinder

Board member

Molinder, MSc in engineering, has more than 25 years of investment activities in the healthcare sector with particular emphasis on biotech and pharma. Lars has worked as investment manager at the Swedish Industrial Development Fund (Industrifonden), sector head of Healthcare at ABN Amro Alfred Berg and as sector head healthcare at Carnegie Investment Bank (presently) Lars has advised in numerous IPO´s and secondary issues as well as public and private M&A in the Nordic Capital Markets, including companies like Calliditas, Cellink, Camurus, Nuevolution, Oncopeptides, Medivir, Wilson Therapeutics, BioArctic, Bonesupport, PledPharma, Alligator Biosciences, Hansa Medical, Recipharm and others.

Jonas Sjögren, M.D.

Board member

Sjögren holds a M.Sc. in Electrical Engineering from Chalmers University of Technology, he is a registered medical doctor from the Sahlgrenska Academy, University of Gothenburg and has an MBA from INSEAD. Sjögren has a long experience as a board member in a variety of industries, stretching from biotech to the consumer tech industry e.g. Alligator Bioscience AB, Storytel AB CMC SPV, Exceca Allocation AB and Delibr AB.